CYTK Cytokinetics (CYTK) Q4 FY25 earnings call
Cytokinetics has transitioned into a global commercial-stage biopharmaceutical company following the landmark approvals of Myqorzo in the U.S., China, and EU for obstructive HCM. The company is focused on executing a disciplined commercial launch in the U.S., with early engagement indicating strong interest, and is preparing for its first European launch in Germany in Q2 2026. Key pipeline readouts, including ACACIA-HCM in non-obstructive HCM, are anticipated in Q2 2026, positioning the company for continued growth and potential label expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CYTK operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Prescribers MYQORZO | 275+In Q1, we saw strong demand with more than 275 unique HCPs prescribing MYQORZO with over 50% from the high-volume CMI writer segment.Source: earnings call transcript | 700+By the end of the quarter, more than 700 unique health care providers in the US have prescribed MYQORZO including approximately 300 physicians from the high-volume CMI writer segment.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.